{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"15.4","value":"1.4"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"5.5","value":"4.9"},{"groupId":"OG002","lowerLimit":"1.1","upperLimit":"2.4","value":"1.3"},{"groupId":"OG003","lowerLimit":"1.3","upperLimit":"3.7","value":"1.6"},{"groupId":"OG004","lowerLimit":"1.9","upperLimit":"5.4","value":"3.3"},{"groupId":"OG005","lowerLimit":"1.3","upperLimit":"2.6","value":"1.5"},{"groupId":"OG006","lowerLimit":"1.2","upperLimit":"2.3","value":"1.4"},{"groupId":"OG007","lowerLimit":"1.6","upperLimit":"3.9","value":"2.8"},{"groupId":"OG008","lowerLimit":"1.2","upperLimit":"1.7","value":"1.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"16"}],"units":"Participants"}],"description":"Progression-free survival is defined as the number of days from study day 1 (first dose of investigational product) to the first observation of disease progression (by modified RECIST; or clinical progression, whichever came first) or death due to any cause. Disease progression by RECIST is defined as at least a 20% increase in the sum of diameters of target lesions in reference to the smallest sum on study and an absolute increase of at least 5 mm; the appearance of any new lesions is also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG000","title":"Part 1 Cohort 1"},{"description":"AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG001","title":"Part 1 Cohort 2"},{"description":"AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)\n\nAMG 479: AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.\n\nAMG 655: AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.","id":"OG002","title":"Part 1 Cohort 3"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Non-squamous NSCLC","id":"OG003","title":"Part 2 Cohort 1"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Squamous Non -Small Cell Lung Cancer (NSCLC)","id":"OG004","title":"Part 2 Cohort 2"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Colorectal Cancer (CRC)","id":"OG005","title":"Part 2 Cohort 3"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Pancreatic Cancer","id":"OG006","title":"Part 2 Cohort 4"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Ovarian Cancer","id":"OG007","title":"Part 2 Cohort 5"},{"description":"AMG 479 18 mg/kg (Q3W) with AMG 655 15 mg/kg (Q3W) Sarcoma","id":"OG008","title":"Part 2 Cohort 6"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from first dose up to 24 months","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}